Active Ingredient History
Blisibimod is a selective antagonist of B-cell activating factor, being developed by Anthera Pharmaceuticals as a treatment for systemic lupus erythematosus. It is currently under active investigation in clinical trials. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Glomerulonephritis, IGA (Phase 3)
Granulomatosis with Polyangiitis (Phase 2)
Lupus Erythematosus, Systemic (Phase 3)
Microscopic Polyangiitis (Phase 2)
Purpura, Thrombocytopenic, Idiopathic (Phase 2/Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue